Plain-English translation of NCT07391839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing MDN-001 Injection, a new treatment for hepatocellular carcinoma (liver cancer) that cannot be surgically removed. The medication uses tiny radioactive microspheres delivered directly into the liver to target cancer cells. Researchers want to learn whether this treatment is safe and how well it works in patients like you.
Many people with advanced liver cancer cannot have surgery to remove their tumors. This trial exists to see whether this new injection therapy could offer a treatment option for patients who have limited choices, and to understand what side effects it may cause.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital to receive a single injection of the medication, which is delivered directly into your liver using imaging guidance. Before treatment, you will have blood tests, imaging scans (MRI or CT), and an echocardiogram to ensure you are healthy enough. After the injection, you will be followed over time with regular visits and imaging to check how well the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
China